in vivo nucleic acid delivery - in vivo-jetPEI®

in vivo nucleic acid delivery - in vivo-jetPEI®

in vivo-jetPEI® is well suited as a delivery vehicle for therapeutic approaches, including gene therapy, genetic vaccination, immune therapy and cancer treatment.

  • Suitable for in vivo delivery of any nucleic acid
  • Proven Track record : over 700 publications
  • Very easy to use: two-step protocol
  • Used for therapeutics and clinical trials worldwide
  • Safe: No inflammatory response triggered
  • Protocols tailored for your application by Polyplus-transfection delivery experts

in vivo-jetPEI® is well suited as a delivery vehicle for therapeutic approaches, including gene therapy, genetic vaccination, immune therapy and cancer treatment.

Request a Quote

Description

in vivo-jetPEI® is the reagent of choice to deliver any type of nucleic acid to mediate gene expression or gene silencing in various tissues. The success of this delivery system relies on its ability to efficiently deliver the appropriate therapeutic nucleic acid into the target tissue or cells with low toxicity and limited immune response. in vivo-jetPEI® is very versatile as it is suitable for the delivery of plasmid DNA, siRNA, shRNA, miRNA, oligonucleotides and mRNA.

Protein expression following plasmid DNA systemic delivery using in vivo-jetPEI ®. Bioluminescent imaging of luciferase expression in living Nude mouse using IVIS 100 camera (Caliper-PerkinElmer) 24 h after gene delivery. pCMVLuc (50 µg) was complexed with in vivo-jetPEI ® in 400 µl of 5% glucose solution and injected into the tail vein.

in vivo-jetPEI® is a very easy-to-use delivery reagent. The protocol consists in preparing the nucleic acid and reagent separately in 5% glucose solution, mixing them together and then, after a 15 min incubation time at room temperature, injecting the nucleic acid/ in vivo-jetPEI® complexes formed into animal. This protocol is suitable for any administration route and any animal model.

in vivo-jetPEI ® protocol. Convenient protocol for delivery of any nucleic acid, using any route of administration in any animal model.

in vivo-jetPEI® has been selected as a delivery vector for several drug development programs due to its safety and delivery efficiency. To fulfill all the quality requirements associated to the use of our reagent in Human, Polyplus-transfection® supplies preclinical grade reagents, as well as cGMP grade in vivo-jetPEI® that are currently used in several ongoing preclinical studies and phase I and II clinical trials. Following in vivo-jetPEI® -mediated systemic delivery of nucleic acid, there is no induction of major pro-inflammatory cytokines and no increase in sera levels of hepatic enzymes (Bonnet et al. (2008), Pharm Res, 25:2972). Hence, in vivo-jetPEI® offers a reliable and safe alternative to viral vectors that can elicit an immune response.

No pro-inflammatory cytokine induced following intravenous delivery of nucleic acid/ in vivo-jetPEI ® complexes. A siRNA (40 ug) was delivered with or without in vivo-jetPEI ®. The level of TNF-α, IL12/IL23, IFNγ and IL6 was measured 1h, 6h, 12h and 6 h after delivery, respectively. The negative control is glucose only, the positive control is an IP injection of E. coli LPS (50 μg).

Examples of citations

Acosta, C., Djouhri, L., Watkins, R., Berry, C., Bromage, K., Lawson, S. N. (2014). TREK2 expressed selectively in IB4-binding C-fiber nociceptors hyperpolarizes their membrane potentials and limits spontaneous pain., J Neurosci 34, 1494-509.

Ellermeier, J., Wei, J., Duewell, P., Hoves, S., Stieg, M. R., Adunka, T., Noerenberg, D., Anders, H. J., Mayr, D., Poeck, H., Hartmann, G., Endres, S., Schnurr, M. (2013). Therapeutic efficacy of bifunctional siRNA combining TGF-beta1 silencing with RIG-I activation in pancreatic cancer., Cancer Res 73, 1709-20.

Wahlquist, C., Jeong, D., Rojas-Munoz, A., Kho, C., Lee, A., Mitsuyama, S., van Mil, A., Park, W. J., Sluijter, J. P., Doevendans, P. A., Hajjar, R. J., Mercola, M. (2014). Inhibition of miR-25 improves cardiac contractility in the failing heart., Nature 508, 531-5.

Zuckermann, M., Hovestadt, V., Knobbe-Thomsen, C.B., Zapatka, M., Northcott, P.A., Schramm, K., Belic, J., Jones, D.T.W., Tschida, B., Moriarity, B., Largaespada, D., Roussel, M.F., Korshunov, A., Reifenberger, G., Pfister, S.M., Lichter, P., Kawauchi, D. and Gronych, J. (2015). Somatic CRISPR/Cas9-mediated tumour suppressor disruption enables versatile brain tumour modelling., Nat Commun 6:7391.

Testimonials

"in vivo-jetPEI® is a very nice reagent to work with!"
– Marie-Line G., Lady Davis Institute, Canada